Technetium Tc-99m Sodium Pertechnetate

Sold as Sodium Pertechnetate Tc 99m. Every FDA application for this active ingredient.

As of Nov 15, 2026, FDA lists 3 applications for Technetium Tc-99m Sodium Pertechnetate (sold as Sodium Pertechnetate Tc 99m), first approved Jul 18, 1974, with 2 new uses approved and 0 published complete response letters.

First approved: Jul 18, 1974
Applications: 3
New uses approved: 2
Complete response letters: 0

Clinical Trials

1 open or ongoing study names this ingredient as an intervention, including as a comparator; newest first. See all

Study	Phase	Status	Posted
VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial CancerMetastatic Endometrial Carcinoma, Recurrent Endometrial Adenocarcinoma · Mayo Clinic	Phase 1	Active, not recruiting	Apr 19, 2017

Applications

NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history


Jul 18, 1974	Sodium Pertechnetate Tc 99mNDA 17471 · New formulation or manufacturer	Ge Healthcare	6	Discontinued
Oct 20, 1976	Sodium Pertechnetate Tc 99mNDA 17321 · New formulation or manufacturer	Sun Pharm Inds Inc	2	Discontinued
Dec 30, 1977	Sodium Pertechnetate Tc 99mNDA 17725 · New formulation or manufacturer	Mallinckrodt	9	Discontinued

Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA